

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
30 January 2025 (30.01.2025)



(10) International Publication Number  
**WO 2025/024523 A1**

(51) International Patent Classification:  
C07H 21/02 (2006.01) C12N 15/113 (2010.01)

(21) International Application Number:  
PCT/US2024/039295

(22) International Filing Date:  
24 July 2024 (24.07.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
63/515,256 24 July 2023 (24.07.2023) US

(71) Applicant: **SANEGENE BIO USA INC.** [US/US]; 300  
Tradecenter Drive, Suite 5500, Woburn, Massachusetts  
01801 (US).

(72) Inventors: **WANG, Weimin**; c/o Sanegene Bio USA Inc.,  
300 Tradecenter Drive, Suite 5500, Woburn, Massachusetts  
01801 (US). **CAI, Xiaochuan**; c/o Sanegene Bio USA Inc.,  
300 Tradecenter Drive, Suite 5500, Woburn, Massachusetts  
01801 (US). **JIANG, Jun**; c/o Sanegene Bio USA Inc.,  
300 Tradecenter Drive, Suite 5500, Woburn, Massachusetts

01801 (US). **WANG, Shiyu**; c/o Sanegene Bio USA Inc.,  
300 Tradecenter Drive, Suite 5500, Woburn, Massachusetts  
01801 (US).

(74) Agent: **CHEN, Chen** et al.; Cooley LLP, ATTN: IP Docket-  
ing Department, 1299 Pennsylvania Avenue NW, Suite 700,  
Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: LIPID-BASED ENHANCEMENT AGENT FOR RNA DELIVERY AND THERAPY




FIG. 1

(57) Abstract: The present disclosure provides a Lipid-Based Enhancement Agent being a compound of Formula (I), (II), (III), or (IV); or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Based Enhancement Agents and conjugates, e.g., in delivering nucleic acid and/or treating or preventing diseases.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*